

# Hypercapnia Suppresses the HIF-dependent Adaptive Response to Hypoxia\*

Received for publication, January 8, 2016, and in revised form, March 24, 2016. Published, JBC Papers in Press, April 4, 2016, DOI 10.1074/jbc.M116.713941

Andrew C. Selfridge<sup>‡§</sup>, Miguel A. S. Cavadas<sup>§¶1</sup>, Carsten C. Scholz<sup>‡§¶||</sup>, Eric L. Campbell<sup>\*\*</sup>, Lynn C. Welch<sup>‡‡2</sup>, Emilia Lecuona<sup>‡‡2</sup>, Sean P. Colgan<sup>\*\*3</sup>, Kim E. Barrett<sup>‡§4</sup>, Peter H. S. Sporn<sup>‡‡§§5</sup>, Jacob I. Sznajder<sup>‡‡2</sup>, Eoin P. Cummins<sup>‡§6</sup>, and Cormac T. Taylor<sup>‡§¶6,7</sup>

From the <sup>‡</sup>School of Medicine and Medical Science, <sup>§</sup>Conway Institute, and <sup>¶</sup>Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland, the <sup>||</sup>Institute of Physiology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland, the <sup>\*\*</sup>University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, the <sup>‡‡</sup>Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, and the <sup>§§</sup>Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612

Molecular oxygen and carbon dioxide are the primary gaseous substrate and product of oxidative metabolism, respectively. Hypoxia (low oxygen) and hypercapnia (high carbon dioxide) are co-incidental features of the tissue microenvironment in a range of pathophysiologic states, including acute and chronic respiratory diseases. The hypoxia-inducible factor (HIF) is the master regulator of the transcriptional response to hypoxia; however, little is known about the impact of hypercapnia on gene transcription. Because of the relationship between hypoxia and hypercapnia, we investigated the effect of hypercapnia on the HIF pathway. Hypercapnia suppressed HIF- $\alpha$  protein stability and HIF target gene expression both in mice and cultured cells in a manner that was at least in part independent of the canonical O<sub>2</sub>-dependent HIF degradation pathway. The suppressive effects of hypercapnia on HIF- $\alpha$  protein stability could be mimicked by reducing intracellular pH at a constant level of partial pressure of CO<sub>2</sub>. Bafilomycin A1, a specific inhibitor of vacuolar-type H<sup>+</sup>-ATPase that blocks lysosomal degradation, prevented the hypercapnic suppression of HIF- $\alpha$  protein. Based on these results, we hypothesize that hypercapnia counter-regulates activation of the HIF pathway by reducing intracellular pH and promoting lysosomal degradation of HIF- $\alpha$  subunits. Therefore, hypercapnia may play a key role in the pathophysiology of diseases where HIF is implicated.

Current atmospheric CO<sub>2</sub> levels are relatively low when compared with those recorded throughout the natural history of the planet (1). Not surprisingly, therefore, a range of organ-

isms as diverse as bacteria, fungi, plants, and mammals mount physiologic responses to hypercapnia (2). It is now clear that CO<sub>2</sub>, like other physiologic gases such as oxygen and nitric oxide, can be sensed by cells and can elicit adaptive transcriptional responses (2–4).

Because O<sub>2</sub> consumption is coupled to CO<sub>2</sub> production, an intimate inverse relationship exists between the levels of these gases in cells and tissues. Furthermore, O<sub>2</sub> and CO<sub>2</sub> levels may become perturbed during certain pathophysiologic states (3, 5). Hypoxia and hypercapnia can co-occur in respiratory disorders such as obstructive sleep apnea syndrome, pneumonia, and chronic obstructive pulmonary disease (6, 7). In acute lung injury hypoxia may arise, whereas permissive hypercapnia is often tolerated as a protective ventilatory strategy in patients presenting with this disorder (8, 9). Hypercapnia and hypoxia also influence inflammatory processes (10–12). During inflammation, oxygen consumption is significantly elevated, leading to tissue hypoxia. It is likely that this also has consequences for tissue CO<sub>2</sub> levels (3, 11).

HIF<sup>8</sup> (which comprises the HIF-1, HIF-2, and HIF-3 isoforms) is the master transcriptional regulator of the cellular response to hypoxia (13). Canonical HIF degradation relies on the activity of O<sub>2</sub>-dependent prolyl hydroxylases 1–3 (14). In normoxia, prolyl hydroxylases enzymatically modify HIF- $\alpha$  subunits on proline residues within the oxygen-dependent degradation domain (ODD) (14). HIF- $\alpha$  is subsequently targeted for ubiquitination and proteasomal destruction, with this reaction being mediated by the von Hippel Lindau (pVHL) E3 ligase complex. The asparaginyl hydroxylase factor inhibiting HIF confers a second mechanism of O<sub>2</sub>-dependent repression by preventing HIF binding to CREB-binding protein/p300. In hypoxia, when oxygen demand exceeds supply, the O<sub>2</sub>-dependent hydroxylases are no longer active. HIF- $\alpha$  stabilizes and translocates to the nucleus, where it dimerizes with its constitutively expressed  $\beta$  subunit. The HIF heterodimer binds to hypoxia response elements at or near promoters and enhancers of genes, where it promotes the formation of a transcriptional complex. HIF regulates the transcription of a host of targets,

\* This work was supported by Science Foundation Ireland (Grant Number 11/PI/1005). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

<sup>1</sup> Present address: Instituto Gulbenkian de Ciência, R. Q. ta Grande 6, 2780-156, Oeiras, Portugal.

<sup>2</sup> Supported by National Institutes of Health Grants HL85534 and HL71643.

<sup>3</sup> Supported by National Institutes of Health Grant DK50189.

<sup>4</sup> Permanently affiliated with the Div. of Gastroenterology, Dept. of Medicine, and Biomedical Science Ph.D. Program, University of California San Diego School of Medicine, La Jolla, CA 92093.

<sup>5</sup> Supported by National Institutes of Health Grant HL107629.

<sup>6</sup> Both authors contributed equally to this work.

<sup>7</sup> To whom correspondence should be addressed: Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland. Tel.: 35-317166732; E-mail: cormac.taylor@ucd.ie.

<sup>8</sup> The abbreviations used are: HIF, hypoxia-inducible factor; ODD, oxygen-dependent degradation domain; pVHL, von Hippel Lindau tumor suppressor protein; CREB, cAMP response element-binding protein; EPO, erythropoietin; DMOG, dimethylxylglycine; Baf-A1, bafilomycin A1; pHi, intracellular pH; pHe, extracellular pH; DMSO, dimethyl sulfoxide.

including those with angiogenic, vasodilatory, inflammatory, and glycolytic functions (13–14). Recently, evidence has emerged for a separate  $O_2$ -independent, non-canonical HIF degradation pathway that is reliant on chaperone-mediated lysosomal autophagy (15–18).

A number of previous publications that predate the discovery of HIF reported the suppression of the HIF-target erythropoietin (EPO) by hypercapnia, although the mechanism underpinning this suppression has not been established (19–24). In this study, we examine the relationship between physiologically relevant levels of  $CO_2$ , the HIF pathway, and the HIF target gene erythropoietin. Because hypoxia and hypercapnia often occur co-incidentally in disease, manipulation of HIF with  $CO_2$  might represent a novel window of opportunity in the treatment of conditions in which hypoxia is a constituent feature.

## Experimental Procedures

**Animal Model of Hypercapnia**—Two separate sets of *in vivo* experiments were performed. In each case, mice were administered an 8-mg intraperitoneal injection of the pharmacologic hypoxia mimetic dimethylxylglycine (DMOG) or the equivalent saline vehicle control (25). Mice were then placed in hypercapnic conditions (10%  $CO_2$ /21%  $O_2$ ) or in room air (0.04%  $CO_2$ /21%  $O_2$ ) for 6 h. Experiment A was performed at Northwestern University, using 9- to 11-week-old male C57BL/6 mice that were sacrificed with Euthasol euthanizing solution. Experiment B was conducted at University of Colorado Denver, with 18- to 20-week old female ODD-Luc mice maintained on an Friend virus B background (26). These mice were anesthetized with isoflurane prior to sacrifice by exsanguination and cervical dislocation. Both sets of mice were sourced from The Jackson Laboratory (Bar Harbor, ME.) The *in vivo* studies were approved by the Institutional Animal Care and Use Committees at Northwestern University and the University of Colorado Denver as appropriate. The experimental set from which each figure originated is referred to in the associated figure legend. EPO values were determined with either the Mesoscale mouse/rat hypoxia serum/plasma kit (Mesoscale Diagnostics, Rockville, MD) or a Quantikine mouse EPO ELISA (R&D Systems, Minneapolis, MN). To extract protein, mouse tissue was homogenized in radioimmune precipitation assay buffer with the TissueLyzer II (Qiagen, Venlo, Netherlands). The homogenized supernatant was subject to three cycles of centrifugation (14,000 rpm  $\times$  10 min) and sonication.

**Cell Culture**—Human HEK 293 embryonic kidney cells, A549 adenocarcinoma alveolar basal epithelial cells, HeLa cervical cancer cells, HCT 116 colorectal carcinoma cells, as well as renal adenocarcinoma RCC4 and 786-O cells were all used for *in vitro* experiments. Cells were maintained according to ATCC (Manassas, VA) recommendations. Cells were incubated at 37 °C in an atmosphere of 21%  $O_2$  and 5%  $CO_2$  prior to experimental exposures.

**Hypercapnic and Hypoxic Exposure *in Vitro***—Cells were exposed to defined atmospheric conditions in environmental chambers (Coy Laboratories, Grass Lake, MI). Experimental atmospheres were designed to mimic the levels of  $CO_2$  and  $O_2$  recorded in pathophysiologic conditions (27, 28). Normocapnia was defined as 5%  $CO_2$  equivalent to 35–37 mmHg (normal

physiologic partial pressure of  $CO_2$ ). Hypercapnia *in vitro* was defined as 7.5%, 10%, 15%, or 20%  $CO_2$ . These values are representative of  $CO_2$  levels encountered in disease that are equivalent to >45 mmHg (physiological hypercapnia partial pressure of  $CO_2$ ) (29). Normoxia was defined as 21%  $O_2$  and hypoxia as 1%  $O_2$ . The levels of hypercapnia utilized did not significantly affect cell viability (data not shown). At the end of each experimental exposure, cell lysates were harvested within the chambers to prevent the confounding effects of reoxygenation and  $CO_2$  desaturation.

**$CO_2$ -buffered Media**—Media were supplemented with either sodium bicarbonate or Tris base to obtain a pH of 7.4 at all  $CO_2$  levels, as described in work published previously (10, 30). Media was pre-equilibrated overnight in the experimental atmosphere. Media pH readings were taken at the beginning and end of each exposure to ensure uniformity between and within experiments as well as across the range of  $CO_2$  concentrations.

**Western Blotting**—Proteins were quantified with a protein assay kit (Bio-Rad) and subsequently resolved in 8–15% polyacrylamide gels. Separated proteins were then transferred to nitrocellulose membranes and incubated overnight in primary antibodies. The following primary antibodies were used: HIF-1 $\alpha$  (610958, 1:500, mouse, BD Biosciences), HIF-1 $\alpha$  (MAB3582, 1:500, mouse, Millipore), HIF-2 $\alpha$  (NB100-122, 1:1000, rabbit, Novus, Littleton, CO), HIF-1 $\beta$  (NB100-982, 1:1000, rabbit, Novus), hydroxylated HIF-1 $\alpha$  (D43B5, 1:1000, rabbit, Cell Signaling Technology, Beverly, MA),  $\beta$ -actin (A5316, 1:10,000, mouse, Sigma-Aldrich, St. Louis, MO), pVHL (2738, 1:1000, rabbit, Cell Signaling Technology), GFP (2555, 1:2000, rabbit, Cell Signaling Technology), and carbonic anhydrase IX (H-120, 1:2000, rabbit, Santa Cruz Biotechnology, Pasa Robles, CA). Secondary antibodies were applied (Cell Signaling Technology), and bands were detected using a chemiluminescence kit (Thermo Scientific, Waltham, MA). Densitometric values were obtained with ImageJ (National Institutes of Health, Bethesda, MD).

**Intracellular pH Assay**—HEK 293 cells were loaded with 5  $\mu$ M BCECF-AM (2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester; Molecular Probes, Eugene, OR) dissolved in Opti-MEM 1 (Life Technologies) and left for 30 min at 5%  $CO_2$ /95% air. The probe was then removed, and cells were incubated in normocapnia (5%  $CO_2$ ) or hypercapnia (10%  $CO_2$ ) for 4 h. At the end of this time, medium was removed, and fluorescence was measured using a plate reader. The fluorophore was excited at 485 nm ( $\lambda_1$ ) and 444 nm ( $\lambda_2$ ), and emission was recorded at 538 nm in each case. BCECF intracellular fluorescence was determined by calculating the ratio of  $\lambda_1/\lambda_2$ .

**Media Mixtures for pH Buffering Experiments**—For the experiments outlined in Fig. 4, C–G, four media mixtures were used to buffer extracellular pH. Dulbecco's modified Eagle's medium 1152 powder (Sigma-Aldrich) was resuspended in water and supplemented with 10% fetal bovine serum and penicillin/streptomycin antibiotic mixture. Defined amounts of sodium bicarbonate ( $NaHCO_3$ ) were added to the media to buffer extracellular pH. In order of increasing acidity, the media contained the following masses and concentrations of  $NaHCO_3$  per 500 ml: mixture 1, 2.21 g, 52.6 mM; mixture 2, 1.23 g, 29.3

## Hypercapnia Suppresses HIF

mM; mixture 3, 0.48 g, 11.43 mM; mixture 4, 0 g, 0 mM. Osmolarity was balanced using NaCl throughout.

**HIF Luciferase Reporter Assay**—HeLa cells were transfected with a firefly luciferase reporter under the control of a hypoxia response element 24 h before the start of experimental exposure. To quantify luciferase activity, cells were lysed with reporter lysis buffer (Promega, Madison, WI). Luciferin/ATP substrate (Promega) was then added to cell lysates, and the luciferase activity was quantified in a luminometer (Bio-Rad).  $\beta$ -Galactosidase under the control of an SV40 promoter was used as a transfection control in these experiments. All values were normalized to  $\beta$ -galactosidase before -fold changes were calculated as described previously (31).


**Quantitative Real-time PCR**—Primers (Eurofins MWG Operon, Ebersberg, Germany) were used to quantify the levels of HIF-1 $\alpha$  (forward primer ACAAGTCACCACAGGAC-AG) and HIF-2 $\alpha$  (forward primer CAACCTGC-AGCCTCAGTG-TATC) mRNA. PCR outputs were normalized to 18S rRNA, and final values were calculated according to the  $\Delta$ Ct method.

**Statistical Analyses**—Data are summarized as mean  $\pm$  S.E. for  $n$  independent experiments. Statistical significance was assessed using a  $t$  test, Mann-Whitney test, or one-way ANOVA followed by the appropriate post test. Within the figures, levels of statistical significance are denoted as follows: \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ ; \*\*\*,  $p \leq 0.001$ ; \*\*\*\*,  $p \leq 0.0001$ ; NS, non-significant.

## Results

**Hypercapnia Suppresses the HIF Pathway in Vivo**—EPO is a prototypic HIF-dependent gene. In a mouse model, we observed a suppressive effect of hypercapnia on serum EPO levels (Fig. 1A). This is consistent with previous studies examining the effect of hypercapnia on EPO expression and indicates the sensitivity of a well characterized HIF target gene to hypercapnia (19–24). Because EPO is preferentially regulated by the HIF-2 isoform, we next investigated the impact of hypercapnia on HIF-2 $\alpha$  protein (32). To activate the HIF response, mice were treated with the hydroxylase inhibitor DMOG prior to exposure to hypercapnia (10% CO<sub>2</sub>) or room air (0.04% CO<sub>2</sub>) for 6 h. DMOG increased the levels of HIF-2 $\alpha$  protein in normocapnia in both brain and liver tissue (Fig. 1B, data not shown for brain). Hepatocytes are the main source of extrarenal EPO in adults (32). In the liver, we found that hypercapnia suppressed DMOG-induced HIF-2 $\alpha$  protein stabilization (Fig. 1B). Similar results were found in brain tissue (data not shown). Although we were technically unable to consistently detect HIF-1 $\alpha$  protein in tissues by immunoblot, we found that DMOG treatment stimulated expression of the HIF-1 target gene, carbonic anhydrase IX, in a manner that was significantly blunted by hypercapnia (data not shown). In contrast, HIF-1 $\beta$ , a constitutively expressed stable subunit that is not subject to O<sub>2</sub>-dependent degradation, was not affected by either DMOG or hypercapnia (data not shown). Taken together, these data suggest that hypercapnia exerts a selectively suppressive effect on HIF- $\alpha$  protein isoforms and downstream genes *in vivo*.

**Hypercapnia Suppresses the HIF Pathway in Vitro**—Consistent with our observations in mice, both basal and DMOG-induced HIF-2 $\alpha$  protein levels were suppressed by hypercapnia




**FIGURE 1. Hypercapnia suppresses the HIF pathway *in vivo*.** A, circulating serum EPO levels in mice exposed to room air (0.04% CO<sub>2</sub>, 21% O<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>, 21% O<sub>2</sub>) for 6 h. Data are presented as percentage EPO change relative to normocapnic mice ( $n = 7$  for all groups except 0.04% CO<sub>2</sub>/DMOG, which is  $n = 6$ ). Statistical significance was determined by  $t$  test. B, representative Western blot and quantitative densitometric analysis for liver HIF-2 $\alpha$  protein normalized to liver  $\beta$ -actin ( $n = 6$ ) in mice treated with DMOG in the presence and absence of hypercapnia. Statistical comparison was made using by one-way ANOVA with Tukey's post test (\*\*\*,  $p$  [teq] 0.001; \*\*,  $p \leq 0.01$  for the comparisons indicated by brackets). All data are presented as mean  $\pm$  S.E. The Western blotting images displayed above originate from contiguous gels. Samples were run in a different order to the way they are presented above, as indicated by the white space. A represents data from experiment A and B mice, whereas B represents data from experiment A mice. MW, molecular weight.

(10% CO<sub>2</sub>) in HEK 293 cells (Fig. 2A). Furthermore, we found that hypercapnia reduced DMOG-stabilized HIF-1 $\alpha$  protein in HEK 293 cells (Fig. 2B). These results were replicated in other epithelial and non-epithelial cell lines (A549, HCT 116, THP-1, and HeLa cells; data not shown). Hypercapnia also decreased the hypoxic stabilization of HIF-1 $\alpha$  protein in HEK 293 and HeLa cells (data not shown). Moreover, hypercapnia suppressed DMOG-induced HIF-1 $\alpha$  protein expression in HEK 293 cells at all degrees of hypercapnia tested (10%, 15%, and 20% CO<sub>2</sub>) (Fig. 2C). An alternative hydroxylase inhibitor, JNJ1935, was also used to increase HIF protein levels (33). Hypercapnia decreased JNJ1935-induced HIF-1 $\alpha$  protein stabilization (Fig. 2D).

To develop our understanding of the hypercapnic suppression of HIF, we attempted to titrate the level of CO<sub>2</sub> required to destabilize HIF protein. HIF-1 $\alpha$  protein levels induced by JNJ1935 were always suppressed by 10% CO<sub>2</sub> but were more variable at 7.5% CO<sub>2</sub> (Fig. 2D). This indicates a switch-like control mechanism where the hypercapnic suppression of HIF occurs above a level of 7.5% CO<sub>2</sub>. Consistent with our *in vivo* studies, HIF-1 $\beta$  protein levels were unaffected by changes in CO<sub>2</sub> tension (Fig. 2E). Thus, hypercapnia suppresses labile elements of the HIF pathway (HIF-1 $\alpha$  and HIF-2 $\alpha$  protein) but not ubiquitously expressed stable subunits (HIF-1 $\beta$  protein) (34). Next, a firefly luciferase reporter was used to measure the effect of CO<sub>2</sub> on HIF-dependent transcriptional activity. In agreement with the data reported above, hypercapnia suppressed HIF-dependent trans-activation (Fig. 2F). In summary, *in vitro* experiments support the observation that hypercapnia suppresses the HIF pathway. The suppression of HIF-1/2 $\alpha$  protein






**FIGURE 2. Hypercapnia suppresses the HIF pathway *in vitro*.** A, representative HEK 293 whole cell lysate HIF-2 $\alpha$  protein immunoblots and densitometry normalized to  $\beta$ -actin from cells treated with or without DMOG (1 mM) and exposed to normocapnia or hypercapnia for 4 h ( $n = 6$ ). B, representative HEK 293 HIF-1 $\alpha$  protein immunoblots and densitometry normalized to  $\beta$ -actin from cells treated with or without DMOG (1 mM) and exposed to normocapnia or hypercapnia for 4 h ( $n = 3$ ). C, HIF-1 $\alpha$  and  $\beta$ -actin immunoblot from HEK 293 whole cell lysates from cells treated with DMOG (1 mM) or DMSO vehicle control and incubated for 4 h in normocapnia (5% CO<sub>2</sub>) or various degrees of hypercapnia (10%, 15%, and 20% CO<sub>2</sub>) ( $n = 3$ ). D, HIF-1 $\alpha$  and  $\beta$ -actin protein immunoblots from HEK 293 whole cell lysates from cells treated with JNJ1935 (100  $\mu$ M) or DMSO vehicle control and placed in either normocapnia (5% CO<sub>2</sub>) or hypercapnia (7.5% CO<sub>2</sub> or 10% CO<sub>2</sub>) for 4 h ( $n = 3$ ). E, HIF-1 $\beta$  normalized to  $\beta$ -actin in HEK 293 whole cell lysates from cells treated with DMOG (1 mM) or DMSO vehicle control and incubated in normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h ( $n = 4$ ). F, a hypoxia response element-driven firefly luciferase construct was used to measure the impact of CO<sub>2</sub> tension on the activity of HIF-dependent transcriptional activity in HeLa cells. Cells were treated with DMOG (1 mM) or DMSO vehicle control and exposed to normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 24 h.  $\beta$ -Galactosidase was used as a transfection control, and all values were normalized to  $\beta$ -galactosidase. -Fold changes were calculated relative to normocapnic DMSO-treated samples at 24 h ( $n = 4$ ). All data are represented as mean  $\pm$  S.E. Statistical significance was determined by one-way ANOVA with Tukey's post test (\*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ ; \*\*\*,  $p \leq 0.001$ ; NS, non-significant for the comparisons indicated by brackets). MW, molecular weight.

by pathophysiologically relevant levels of CO<sub>2</sub> was consistently recorded across multiple cell types.

**Hypercapnia Does Not Affect Canonical HIF Degradation—**To provide mechanistic insights into hypercapnic suppression of HIF signaling, we initially examined whether CO<sub>2</sub> modulates HIF-1/2 $\alpha$  mRNA. Hypercapnia did not decrease mRNA for either gene (Figs. 3, A and B). Therefore, hypercapnia likely exerts its suppressive influence on HIF-1/2 $\alpha$  at a post-transcriptional level. The major mechanism known to regulate HIF- $\alpha$  protein levels is the canonical O<sub>2</sub>-dependent HIF deg-

radation pathway (35). Because CO<sub>2</sub> is a product of the HIF hydroxylation reaction, we considered the possibility that HIF hydroxylation could be increased by hypercapnia. However, the hydroxylated form of HIF-1 $\alpha$  was suppressed rather than enhanced by elevated CO<sub>2</sub> (Fig. 3C), suggesting that this is not the means by which hypercapnia destabilizes HIF protein. We also hypothesized that hypercapnia might increase proteasomal degradation of HIF. Nevertheless, in the presence of a proteasomal inhibitor, hypercapnia still suppressed both hydroxylated and total HIF-1 $\alpha$  protein levels (Fig. 3C).



**FIGURE 3. Hypercapnia does not affect canonical HIF degradation.** A, quantitative real-time PCR for HIF-1α mRNA from HEK 293 cells exposed to normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h (n = 3). B, quantitative real-time PCR for HIF-2α mRNA from HEK 293 cells exposed to normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h (n = 3). C, representative immunoblots of HIF-1α, hydroxylated HIF-1α, and β-actin protein from HEK 293 whole cell lysates derived from cells incubated in normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h with DMOG (1 mM) or DMSO vehicle control as well as MG132 (10 μM) (n = 3). Densitometry is provided for hydroxylated HIF-1α normalized to β-actin. D, representative immunoblot and densitometry for ODD-GFP and β-actin in HCT 116 cell whole cell lysates. Cells stably transfected with an ODD-GFP construct were exposed to normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h with DMOG (1 mM) or DMSO vehicle control (n = 4). E, representative Western blot of von Hippel-Lindau and β-actin protein in HEK 293 whole cell lysates from cells exposed to normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h with DMOG (1 mM) or DMSO vehicle control (n = 3). F, representative Western blot and densitometry for HIF-2α relative to β-actin extracted from RCC 786-O whole cell lysates extracted from cells incubated in normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) with DMOG (1 mM) or DMSO vehicle control for 4 h (n = 3). G, representative Western blot and densitometry for HIF-2α relative to β-actin in RCC4 whole cell lysates from cells exposed to normocapnia (5% CO<sub>2</sub>) or hypercapnia (20% CO<sub>2</sub>) for 8 h (n = 4). Data are represented as mean ± S.E. Statistical significance was determined by one-way ANOVA with Tukey's post test (\*, p ≤ 0.05; \*\*\*, p ≤ 0.001 for the comparisons indicated by brackets). The Western blotting images displayed above all originate from contiguous gels. The samples in C were run on the same gel in a different order to the way in which they are presented above, as indicated by the white space. MW, molecular weight.

Thus, hypercapnia does not induce proteasomal degradation of HIF.

Given the fact that HIF-1/2α subunits both contain an ODD (13) and that both proteins are sensitive to hypercapnia, we proposed that this region might also be responsive to CO<sub>2</sub>. To investigate this hypothesis, experiments were conducted with cells transfected with an ODD-GFP construct (36). We found that hypercapnia did not suppress the DMOG-induced expres-

sion of the ODD region of HIF (Fig. 3D). Therefore, the ODD confers O<sub>2</sub> sensitivity, but this isolated HIF-1α domain is not suppressed by hypercapnia. The inability of hypercapnia to suppress the isolated ODD region further indicates that the effect of CO<sub>2</sub> on HIF-α expression is likely independent of the canonical O<sub>2</sub>-dependent degradation pathway. To further test this important point, we next evaluated whether hypercapnia alters the levels of pVHL protein, another key component of the

canonical HIF degradation machinery. However, the expression of pVHL remained unaffected by either hypercapnia or DMOG treatment (Fig. 3E). We subsequently examined whether a functional pVHL pathway is required for the hypercapnic suppression of HIF. To address this, we used two renal cell carcinoma cell lines that do not express functional pVHL and consequently display endogenous HIF protein stabilization. We found that hypercapnia suppressed DMOG-induced HIF-2 $\alpha$  protein in 786-O cells and endogenous HIF-2 $\alpha$  protein expression in RCC4 cells (Fig. 3, F and G). These results support the concept that pVHL is not required for the hypercapnic suppression of HIF. Together, these data demonstrate that the hypercapnic suppression of HIF does not occur via the canonical O<sub>2</sub>-dependent pVHL/proteasome-mediated HIF degradation pathway.

**Hypercapnic Suppression of HIF Is Mediated by Lysosomal Degradation**—Hypercapnia causes cellular acidosis via the conversion of elevated CO<sub>2</sub> and H<sub>2</sub>O into carbonic acid, which rapidly disassociates into bicarbonate and H<sup>+</sup> ions. Recently, an O<sub>2</sub>-independent mechanism of HIF protein degradation has been described involving lysosomes (15–18). Because an acidic environment is optimal for lysosomal functioning, we focused on this particular non-canonical HIF degradative pathway (37). Vacuolar H<sup>+</sup>-ATPases are ubiquitous proton pumps that are up-regulated at reduced pHi (38). To examine the role of lysosomal degradation in the hypercapnic suppression of HIF, we used bafilomycin A1 (Baf-A1). Baf-A1 is a specific inhibitor of vacuolar H<sup>+</sup>-ATPase and, as such, prevents the vacuolar H<sup>+</sup>-ATPase-mediated acidification of lysosomes, thus reducing autophagic degradation (39). Incubation with Baf-A1 increased both basal and DMOG-stabilized HIF-1 $\alpha$  protein in normocapnia in a dose-dependent manner (Fig. 4A). We subsequently investigated whether an increase in lysosomal degradation is responsible for the hypercapnic suppression of HIF. Interestingly, Baf-A1 treatment prevented the hypercapnia-induced decrease of HIF-1 $\alpha$  protein (Fig. 4B). This suggests that the hypercapnic suppression of HIF-1 $\alpha$  protein is mediated at least in part by lysosomal degradation and that an acidic environment within the lysosome is required to mediate this effect.

We next focused on evaluating whether the suppressive effects of hypercapnia on HIF- $\alpha$  protein could be recapitulated by artificially reducing extracellular pH. Hypercapnia reduced intracellular pH compared with normocapnia, as measured by BCECF fluorescence (data not shown). Using media buffered with different amounts of sodium bicarbonate, we found that the stabilization of DMOG-induced HIF-1 $\alpha$  and HIF-2 $\alpha$  protein was affected by the change in pHe and pHi (Fig. 4, C and D; pHi data not shown). In normocapnia, decreasing pHi with more acidic extracellular media resulted in HIF-1 $\alpha$  suppression (Fig. 4D). In hypercapnia, decreasing pHi with more acidic extracellular media also decreased HIF-1 $\alpha$  and HIF-2 $\alpha$  protein stabilization (Fig. 4, C and D). In contrast, HIF-1 $\beta$  protein levels were unaffected by pHe and pHi (Fig. 4E). Similarly, hypoxia-induced HIF1/2 $\alpha$  protein stabilization can also be suppressed by elevated CO<sub>2</sub> or by decreasing pHe (Fig. 4, F and G). These data demonstrate that HIF stabilization is sensitive to changes in pH comparable with those experienced during hypercapnia. Taken together, these results demonstrate that it is possible to

mimic the suppressive effect of hypercapnia on HIF- $\alpha$  protein by reducing pHi.


Based on these data, we hypothesize that the hypercapnic suppression of HIF is due to non-canonical O<sub>2</sub>-independent lysosomal degradation of HIF- $\alpha$  protein. Pharmacological inhibition of lysosomal activity can prevent hypercapnia-dependent degradation of HIF- $\alpha$ . Both hypercapnia exposure and exogenously reducing pH can destabilize HIF- $\alpha$ . The extent to which hypercapnia *per se* or the change in media pH associated with hypercapnic acidosis are responsible for HIF- $\alpha$  degradation is not yet fully elucidated.

## Discussion

Hypoxia and hypercapnia are often concurrent microenvironmental features at a cellular level and can also co-incidentally occur in disease (3, 5, 6). However, despite the close association between these gases, the impact of CO<sub>2</sub> on cellular responses to low O<sub>2</sub> remain poorly understood. Here we provide evidence of suppression of the hypoxic response by hypercapnia as a counter-regulatory mechanism reducing the activation of the HIF pathway. Using an animal model of hypercapnia, we demonstrated that the HIF-2 target EPO is suppressed by high CO<sub>2</sub>. Hypercapnia also impaired the accumulation of HIF-2 $\alpha$  protein *in vivo* in the presence of the hypoxia mimetic DMOG. Hypercapnic suppression of HIF-1/2 $\alpha$  protein was recorded in several cell lines of diverse origin. Furthermore, HIF-dependent transcriptional activity was diminished by hypercapnia. Lysosomal inhibition using Baf-A1 prevented the hypercapnic suppression of HIF-1 $\alpha$  protein. In our *in vitro* model, pHi was decreased by high CO<sub>2</sub>, and we found that artificially decreasing pHe and pHi destabilized HIF-1/2 $\alpha$  protein in normocapnia and hypercapnia. Thus, we propose that the low pHi conditions present in hypercapnia may facilitate lysosomal degradation of HIF- $\alpha$  protein.

The degradation of HIF protein by non-canonical, O<sub>2</sub>-independent lysosomal chaperone-mediated autophagy is becoming increasingly appreciated (15–18, 40–42). HIF-1 $\alpha$  is targeted for lysosomal degradation via a specific non-canonical KFERQ-like chaperone-mediated autophagy pentapeptide at positions 529–533 (NEFKL) in the ODD (17). We analyzed HIF-2 $\alpha$  according to the criteria for identifying KFERQ-like motifs (43) and found a similar chaperone-mediated autophagy sequence at positions 494–497 (NDLKI). Although in our experiments the isolated ODD region was not suppressed by hypercapnia, it is possible that the full HIF-1 $\alpha$  protein sequence is needed to facilitate the interaction between HIF-1 $\alpha$  and the mediators of lysosomal degradation. The chaperone protein HSPA8 and the lysosome membrane receptor LAMP2A have been implicated in the lysosomal degradation of HIF-1 $\alpha$  (17). This process is also contingent upon Lys-63-linked ubiquitination of HIF-1 $\alpha$  by the ubiquitin E3 ligase STUB1 (18). Lysosomal degradation of HIF-1 $\alpha$  is activated by nutrient deprivation, and in livers extracted from starved animals, the localization of HIF-1 $\alpha$  in lysosomes is increased (17, 18). In the context of our results, the acidic pH conditions extant in hypercapnia may deprive cells nutritionally, and they respond to this challenge by lysosomally degrading HIF- $\alpha$  protein. Although we report an association between hypercapnia and selective





**FIGURE 4. Hypercapnic suppression of HIF is mediated by lysosomal degradation.** A, Western blot and densitometry for HIF-1α and β-actin in HEK 293 whole cell lysates derived from cells exposed to normocapnia (5% CO<sub>2</sub>) for 4 h after treatment with DMOG (1 mM), baflomycin A1 (125 and 250 nM), or DMSO vehicle control (*n* = 4). B, representative Western blot and densitometry for HIF-1α and β-actin protein in HEK 293 whole cell lysates derived from cells after exposure to normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) for 4 h after application of DMOG (1 mM), baflomycin A1 (125 nM), or DMSO vehicle control as indicated (*n* = 4). In A and B, the data (not normally distributed) were analyzed by Mann-Whitney test for the comparisons indicated by the brackets (\*, *p* ≤ 0.05; NS, non-significant). C–E, medium mixtures were buffered with different quantities of sodium bicarbonate to alter pH<sub>e</sub>. HEK 293 cells were incubated for 4 h in normocapnia (5% CO<sub>2</sub>) or hypercapnia (10% CO<sub>2</sub>) with DMOG (1 mM) or DMSO vehicle control with these medium mixtures. pH<sub>e</sub> values are displayed alongside the figures. These samples were measured for levels of HIF-1α protein (C), and membranes were subsequently reblotted for HIF-2α (D) and HIF-1β protein (E). Representative immunoblots and quantitative densitometry for each of these proteins normalized to β-actin are shown (*n* = 3). F and G, medium mixtures were buffered with different quantities of sodium bicarbonate to alter pH<sub>e</sub>. HEK 293 cells were incubated for 24 h in normoxic normocapnia (21% O<sub>2</sub>, 5% CO<sub>2</sub>), hypoxic normocapnia (1% O<sub>2</sub>, 5% CO<sub>2</sub>), or hypoxic hypercapnia (1% O<sub>2</sub>, 10% CO<sub>2</sub>) with these medium mixtures. pH<sub>e</sub> values are displayed alongside the figures. Levels of HIF-1α (F) and HIF-2α (G) protein were assessed by Western blot. Representative immunoblots and quantitative densitometry for each of these proteins normalized to β-actin are shown (*n* = 3). Data are represented as mean ± S.E. The Western blotting images displayed above all originate from contiguous gels. The samples in B were run on the same gel in a different order to the way in which they are presented above, as indicated by the white space. MW, molecular weight.

lysosomal degradation of HIF- $\alpha$  protein, elevated CO<sub>2</sub> has recently been demonstrated to inhibit macroautophagy in macrophages (44).

A number of publications that predate the discovery of HIF document the hypercapnic suppression of EPO levels (19–24). Our study implicates the CO<sub>2</sub>-mediated reduction of EPO as being attributable to hypercapnic suppression of the HIF pathway. Previous papers theorized that hypercapnic repression of EPO is due to increased pulmonary ventilation and subsequent reoxygenation at sites of EPO synthesis (19–24). However, Gates *et al.* (12) recorded only a modest increase in arterial blood gas oxygenation upon exposure for 2 days. The results of our animal studies are concordant with our *in vitro* data despite the fact that cells are not subject to reoxygenation. Given this evidence, we can infer that the CO<sub>2</sub>-mediated reduction in EPO is likely due at least in part to HIF suppression rather than the effects of systemic reoxygenation. Recent works that have demonstrated the ability of 100% CO<sub>2</sub> to suppress hypoxic responses in tumors are supportive of our findings (45–48). Compared with room air controls, 100% CO<sub>2</sub> was found to reduce HIF-1 $\alpha$  stabilization and VEGF mRNA expression in mice implanted with a malignant human histiocytoma. 100% CO<sub>2</sub> also decreased tumor growth while augmenting the effectiveness of chemotherapeutic doxorubicin treatment (45–48). Suppression of the HIF pathway by hypercapnia is of clinical significance given the occurrence of hypoxia and its sequelae in numerous diseases. Depending on the cause of the constitutive hypoxia, it may be favorable to either activate or suppress HIF (35). During inflammation and colitis, HIF exerts a protective effect (11, 49, 50). In contrast, in cancer, intratumoral hypoxia and genetic mutations result in the up-regulation of HIF-1 $\alpha$ , and the activation of HIF can promote tumorigenesis (35). Renal cell carcinomas are prone to generating pVHL-deficient mutations, and, as a result, HIF becomes endogenously stabilized, worsening the prognosis (51). In pVHL-negative renal cell carcinoma tumors, we can speculate that hypercapnia could be utilized as a means of decreasing HIF stabilization beyond the pVHL-dependent canonical HIF degradation pathway. Conversely, the impact of modulating CO<sub>2</sub> tension should also be investigated in disorders where HIF promotes recovery.

In the future, the relationship between O<sub>2</sub> and CO<sub>2</sub> levels in conditions such as inflammation and cancer should be tested experimentally. Interestingly, immune cells extracted from patients with chronic obstructive pulmonary disease have a 3-fold decreased stabilization of HIF-1 $\alpha$  in response to hypoxic exposure for 24 h compared with healthy individuals. However, the contribution of hypercapnia to this defective HIF response has not yet been examined (52). Further studies are warranted to assess the direct associations between the levels of CO<sub>2</sub>, lysosomal degradation, and those of HIF protein *in vivo* and would support the pathobiological relevance of our findings. The potential for hypercapnic acidosis to induce structural changes and subsequent denaturation of HIF- $\alpha$  subunits also needs to be tested experimentally (53).

Thus, the repertoire of biological processes impacted by CO<sub>2</sub> continues to grow (2). In this vein, our study demonstrates the ability of physiologically relevant levels of CO<sub>2</sub> to counter-regulate HIF activation. CO<sub>2</sub> consistently suppresses both HIF- $\alpha$

protein and HIF-dependent targets *in vivo* and *in vitro*. Hypercapnia appears to exert these suppressive effects at least in part by reducing pHi, which facilitates the non-canonical lysosomal degradation of HIF- $\alpha$  protein. It is likely that, in pathophysiological conditions where high CO<sub>2</sub> exists, the hypercapnic suppression of the HIF pathway is an important feature of the disease microenvironment. The inhibition of the adaptive hypoxic response by CO<sub>2</sub> represents a novel therapeutic option in diseases in which the HIF pathway is implicated.

**Author Contributions**—A. C. S. performed all experimental work, except for that shown in Fig. 2F. C. C. S. and E. L. C. contributed data toward Fig. 1A. A. C. S., J. I. S., P. H. S. S., E. C. P., and C. T. T. designed the research. A. C. S., L. C. W., E. L. C., E. L., and E. C. carried out the *in vivo* studies. A. C. S., M. A. S. C., S. P. C., K. E. B., J. I. S., P. H. S. S., E. P. C., and C. T. T. analyzed the data. A. C. S., K. E. B., E. P. C., and C. T. T. wrote the paper.

## References

- Rothman, D. H. (2002) Atmospheric carbon dioxide levels for the last 500 million years. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 4167–4171
- Cummins, E. P., Selfridge, A. C., Sporn, P. H., Sznajder, J. I., and Taylor, C. T. (2014) Carbon dioxide-sensing in organisms and its implications for human disease. *Cell. Mol. Life Sci.* **71**, 831–845
- Taylor, C. T., and Cummins, E. P. (2011) Regulation of gene expression by carbon dioxide. *J. Physiol.* **589**, 797–803
- Oliver, K. M., Lenihan, C. R., Bruning, U., Cheong, A., Laffey, J. G., McLoughlin, P., Taylor, C. T., and Cummins, E. P. (2012) Hypercapnia induces cleavage and nuclear localization of RelB protein, giving insight into CO<sub>2</sub> sensing and signaling. *J. Biol. Chem.* **287**, 14004–14011
- Bergfeld, G. R., and Forrester, T. (1992) Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. *Cardiovasc. Res.* **26**, 40–47
- Krieger, J., Sforza, E., Apprill, M., Lampert, E., Weitzenblum, E., and Ratomaharo, J. (1989) Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. *Chest* **96**, 729–737
- Budweiser, S., Jörres, R. A., and Pfeifer, M. (2008) Treatment of respiratory failure in COPD. *Int. J. Chron. Obstruct. Pulmon. Dis.* **3**, 605–618
- Contreras, M., Masterson, C., and Laffey, J. G. (2015) Permissive hypercapnia: what to remember. *Curr. Opin. Anaesthesiol.* **28**, 26–37
- Vohwinkel, C. U., Hoegl, S., and Eltzschig, H. K. (2015) Hypoxia signaling during acute lung injury. *J. Appl. Physiol.* **119**, 1157–1163
- Cummins, E. P., Oliver, K. M., Lenihan, C. R., Fitzpatrick, S. F., Bruning, U., Scholz, C. C., Slattery, C., Leonard, M. O., McLoughlin, P., and Taylor, C. T. (2010) NF- $\kappa$ B links CO<sub>2</sub> sensing to innate immunity and inflammation in mammalian cells. *J. Immunol.* **185**, 4439–4445
- Colgan, S. P., and Taylor, C. T. (2010) Hypoxia: an alarm signal during intestinal inflammation. *Nat. Rev. Gastroenterol. Hepatol.* **7**, 281–287
- Gates, K. L., Howell, H. A., Nair, A., Vohwinkel, C. U., Welch, L. C., Beitel, G. J., Hauser, A. R., Sznajder, J. I., and Sporn, P. H. (2013) Hypercapnia impairs lung neutrophil function and increases mortality in murine pneumodermatitis pneumonia. *Am. J. Respir. Cell Mol. Biol.* **49**, 821–828
- Semenza, G. L. (2012) Hypoxia-inducible factors in physiology and medicine. *Cell* **148**, 399–408
- Schofield, C. J., and Ratcliffe, P. J. (2004) Oxygen sensing by HIF hydroxylases. *Nat. Rev. Mol. Cell Biol.* **5**, 343–354
- Hubbi, M. E., Gilkes, D. M., Hu, H., Kshitiz, Ahmed, I., and Semenza, G. L. (2014) Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1 $\alpha$  to promote cell-cycle progression. *Proc. Natl. Acad. Sci. U.S.A.* **111**, E3325–E3334
- Hubbi, M. E., Hu, H., Kshitiz, Ahmed, I., Levchenko, A., and Semenza, G. L. (2013) Chaperone-mediated autophagy targets hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) for lysosomal degradation. *J. Biol. Chem.* **288**, 10703–10714



17. Ferreira, J. V., Fôfo, H., Bejarano, E., Bento, C. F., Ramalho, J. S., Girão, H., and Pereira, P. (2013) STUB1/CHIP is required for HIF1A degradation by chaperone-mediated autophagy. *Autophagy* **9**, 1349–1366
18. Ferreira, J. V., Soares, A. R., Ramalho, J. S., Pereira, P., and Girao, H. (2015) K63 linked ubiquitin chain formation is a signal for HIF1A degradation by chaperone-mediated autophagy. *Sci. Rep.* **5**, 10210
19. Zucali, J. R., Lee, M., and Mirand, E. A. (1978) Carbon dioxide effects on erythropoietin and erythropoiesis. *J. Lab. Clin. Med.* **92**, 648–655
20. Wolf-Priessnitz, J., Schooley, J. C., and Mahlmann, L. J. (1978) Inhibition of erythropoietin production in unanesthetized rabbits exposed to an acute hypoxic-hypercapnic environment. *Blood* **52**, 153–162
21. Baker, R., Zucali, J. R., Baker, B. J., and Strauss, J. (1984) Erythropoietin and intrarenal oxygenation in hypercapnic versus normocapnic hypoxemia. *Adv. Exp. Med. Biol.* **169**, 597–609
22. Cohen, R. A., Miller, M. E., Garcia, J. F., Moccia, G., and Cronkite, E. P. (1981) Regulatory mechanism of erythropoietin production: effects of hypoxemia and hypercarbia. *Exp. Hematol.* **9**, 513–521
23. Miller, M. E., and Howard, D. (1979) Modulation of erythropoietin concentrations by manipulation of hypercarbia. *Blood Cells* **5**, 389–403
24. Eckardt, K. U., Kurtz, A., and Bauer, C. (1990) Triggering of erythropoietin production by hypoxia is inhibited by respiratory and metabolic acidosis. *Am. J. Physiol.* **258**, R678–683
25. Cummins, E. P., Seebaluck, F., Keely, S. J., Mangan, N. E., Callanan, J. J., Fallon, P. G., and Taylor, C. T. (2008) The hydroxylase inhibitor dimethylloxalylglycine is protective in a murine model of colitis. *Gastroenterology* **134**, 156–165
26. Safran, M., Kim, W. Y., O'Connell, F., Flippin, L., Günzler, V., Horner, J. W., Depinho, R. A., and Kaelin, W. G., Jr. (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 105–110
27. Ahmadi, Z., Bornefalk-Hermansson, A., Franklin, K. A., Midgren, B., and Ekstrom, M. P. (2014) Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease: a population-based prospective study. *Respiratory research* **15**, 30
28. Carreau, A., El Hafny-Rahbi, B., Matejuk, A., Grillon, C., and Kieda, C. (2011) Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. *J. Cell. Mol. Med.* **15**, 1239–1253
29. Bautista, A. F., and Akca, O. (2013) Hypercapnia: is it protective in lung injury? *Med. Gas. Res.* **3**, 23
30. Vadász, I., Dada, L. A., Briva, A., Helenius, I. T., Sharabi, K., Welch, L. C., Kelly, A. M., Grzesik, B. A., Budinger, G. R., Liu, J., Seeger, W., Beitel, G. J., Gruenbaum, Y., and Sznajder, J. I. (2012) Evolutionary conserved role of c-Jun-N-terminal kinase in CO<sub>2</sub>-induced epithelial dysfunction. *PLoS ONE* **7**, e46696
31. Bruning, U., Fitzpatrick, S. F., Frank, T., Birtwistle, M., Taylor, C. T., and Cheong, A. (2012) NFκB and HIF display synergistic behaviour during hypoxic inflammation. *Cell. Mol. Life Sci.* **69**, 1319–1329
32. Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., and Haase, V. H. (2007) Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin *in vivo*. *J. Clin. Invest.* **117**, 1068–1077
33. Barrett, T. D., Palomino, H. L., Brondstetter, T. I., Kanelakis, K. C., Wu, X., Haug, P. V., Yan, W., Young, A., Hua, H., Hart, J. C., Tran, D. T., Venkatesan, H., Rosen, M. D., Peltier, H. M., Sepassi, K., Rizzolio, M. C., Bembek, S. D., Mirzadegan, T., Rabinowitz, M. H., and Shankley, N. P. (2011) Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. *Mol. Pharmacol.* **79**, 910–920
34. Dengler, V. L., Galbraith, M. D., and Espinosa, J. M. (2014) Transcriptional regulation by hypoxia inducible factors. *Crit. Rev. Biochem. Mol. Biol.* **49**, 1–15
35. Hewitson, K. S., McNeill, L. A., and Schofield, C. J. (2004) Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. *Curr. Pharm. Des.* **10**, 821–833
36. Hagen, T., Taylor, C. T., Lam, F., and Moncada, S. (2003) Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. *Science* **302**, 1975–1978
37. Schulze, H., Kolter, T., and Sandhoff, K. (2009) Principles of lysosomal membrane degradation: cellular topology and biochemistry of lysosomal lipid degradation. *Biochim. Biophys. Acta* **1793**, 674–683
38. Lang, K., Wagner, C., Haddad, G., Burnekova, O., and Geibel, J. (2003) Intracellular pH activates membrane-bound Na<sup>+</sup>/H<sup>+</sup> exchanger and vacuolar H<sup>+</sup>-ATPase in human embryonic kidney (HEK) cells. *Cell Physiol. Biochem.* **13**, 257–262
39. Yamamoto, A., Tagawa, Y., Yoshimori, T., Moriyama, Y., Masaki, R., and Tashiro, Y. (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. *Cell Struct. Funct.* **23**, 33–42
40. Yan, Z. W., Hou, J. K., He, W., Fan, L., and Huang, Y. (2013) Chloroquine enhances cobalt chloride-induced leukemic cell differentiation via the suppression of autophagy at the late phase. *Biochem. Biophys. Res. Commun.* **430**, 926–932
41. Egger, M. E., Huang, J. S., Yin, W., McMasters, K. M., and McNally, L. R. (2013) Inhibition of autophagy with chloroquine is effective in melanoma. *J. Surg. Res.* **184**, 274–281
42. Semenza, G. L. (2006) Baffled by bafilomycin: an anticancer agent that induces hypoxia-inducible factor-1α expression. *Mol. Pharmacol.* **70**, 1841–1843
43. Kaushik, S., and Cuervo, A. M. (2012) Chaperone-mediated autophagy: a unique way to enter the lysosome world. *Trends Cell Biol.* **22**, 407–417
44. Casalino-Matsuda, S. M., Nair, A., Beitel, G. J., Gates, K. L., and Sporn, P. H. (2015) Hypercapnia inhibits autophagy and bacterial killing in human macrophages by increasing expression of Bcl-2 and Bcl-xL. *J. Immunol.* **194**, 5388–5396
45. Onishi, Y., Kawamoto, T., Ueha, T., Kishimoto, K., Hara, H., Fukase, N., Toda, M., Harada, R., Minoda, M., Sakai, Y., Miwa, M., Kurosaka, M., and Akisue, T. (2012) Transcutaneous application of carbon dioxide (CO<sub>2</sub>) induces mitochondrial apoptosis in human malignant fibrous histiocytoma *in vivo*. *PLoS ONE* **7**, e49189
46. Takeda, D., Hasegawa, T., Ueha, T., Imai, Y., Sakakibara, A., Minoda, M., Kawamoto, T., Minamikawa, T., Shibuya, Y., Akisue, T., Sakai, Y., Kurosaka, M., and Komori, T. (2014) Transcutaneous carbon dioxide induces mitochondrial apoptosis and suppresses metastasis of oral squamous cell carcinoma *in vivo*. *PLoS ONE* **9**, e100530
47. Onishi, Y., Ueha, T., Hara, H., Fukase, N., Toda, M., Harada, R., Sakai, Y., Miwa, M., Nishida, K., Kuroda, R., Kurosaka, M., and Akisue, T. (2012) Transcutaneous application of carbon dioxide (CO<sub>2</sub>) enhances chemosensitivity by reducing hypoxic conditions in human malignant fibrous histiocytoma. *J. Cancer Sci. Ther.* **4**, 174–181
48. Iwata, E., Hasegawa, T., Takeda, D., Ueha, T., Kawamoto, T., Akisue, T., Sakai, Y., and Komori, T. (2016) Transcutaneous carbon dioxide suppresses epithelial-mesenchymal transition in oral squamous cell carcinoma. *Int. J. Oncol.* **48**, 1493–1498
49. Tambuwala, M. M., Manresa, M. C., Cummins, E. P., Aversa, V., Coulter, I. S., and Taylor, C. T. (2015) Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis. *J. Control. Release* **217**, 221–227
50. Schaible, B., McClean, S., Selfridge, A., Broquet, A., Asehnoune, K., Taylor, C. T., and Schaffer, K. (2013) Hypoxia modulates infection of epithelial cells by *Pseudomonas aeruginosa*. *PLoS ONE* **8**, e56491
51. Shinojima, T., Oya, M., Takayanagi, A., Mizuno, R., Shimizu, N., and Mura, M. (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α. *Carcinogenesis* **28**, 529–536
52. To, M., Yamamura, S., Akashi, K., Charron, C. E., Barnes, P. J., and Ito, K. (2012) Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. *Chest* **141**, 1233–1242
53. Stigter, D., Alonso, D. O., and Dill, K. A. (1991) Protein stability: electrostatics and compact denatured states. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 4176–4180